Monitor for any future clinical trial initiations or partnership expansions involving these patent applications. No near-term revenue or regulatory catalyst is indicated.
Price Chart
Executive Summary
SciSparc subsidiary NeuroThera announced the publication of three U.S. patent applications covering combinations of its PEA technology with LSD, ketamine, and ibogaine for mental health and substance use disorders. This is a non-financial, early-stage IP milestone with no clinical data, revenue, or near-term catalyst.
Key Facts
- Three U.S. patent applications published covering combinations of NeuroThera's PEA technology with LSD, ketamine, and ibogaine.
- Applications cover potential therapeutic uses for depression, PTSD, pain, and substance use disorders.
- Builds on a prior patent application covering MDMA + N-acylethanolamines for PTSD, anxiety, and eating disorders.
- SciSparc is a clinical-stage company with no approved products; its primary programs are SCI-110 and SCI-210 based on cannabinoids.
Financial Impact
No financial figures disclosed; patent portfolio expansion is an early-stage IP event with no immediate revenue impact.
Risk Factors
- Patent applications are published but not yet granted; no guarantee of issuance or commercial viability.
- SciSparc/NeuroThera have no approved products and limited cash runway; early-stage IP does not change fundamental risk profile.
- Psychedelic-based therapies face significant regulatory and clinical development hurdles.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-102810 |
| Document: ea030637702ex99-1.htm | 0001213900-26-102810 |
| Document: 0001213900-26-102810-index-headers.html | 0001213900-26-102810 |
| Document: 0001213900-26-102810-index.html | 0001213900-26-102810 |
| Document: 0001213900-26-102810.txt | 0001213900-26-102810 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $1.29 | awaiting T+5 | — | $1.29 (−0.04%) |
Oct 23, 2026 3d ago | 6-K | $1.09 | awaiting T+5 | — | $1.29 (+18.35%) |
Oct 22, 2026 4d ago | Press Release | $1.20 | awaiting T+5 | — | $1.29 (+7.50%) |
Oct 15, 2026 11d ago | 6-K | $2.00 $1.20 | ▲ +40.00% | ▲ +38.99% | $1.29 (+35.50%) |
Oct 15, 2026 11d ago | 6-K | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $1.29 (−35.50%) |
Oct 15, 2026 11d ago | Press Release | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $1.29 (−35.50%) |
Oct 7, 2026 19d ago | 6-K | $4.64 $3.63 | ▼ −21.77% | ▼ −20.79% | $1.29 (−72.20%) |
Sep 30, 2026 26d ago | 6-K | $4.55 $4.43 | ▲ +2.64% | ▲ +3.94% | $1.29 (+71.65%) |
Sep 24, 2026 4w ago | 6-K | $5.39 $4.55 | ▼ −15.58% | ▼ −15.17% | $1.29 (−76.07%) |
Sep 23, 2026 4w ago | Press Release | $5.01 $4.72 | ▼ −5.79% | ▼ −5.11% | $1.29 (−74.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers